You are here

FDA Approves Pazeo (Olopatadine) Solution for Ocular Allergy Itch Relief

Product launch expected in March

The FDA has approved Pazeo (olopatadine hydrochloride ophthalmic solution 0.7%, Alcon) for the treatment of ocular itching associated with allergic conjunctivitis. The solution is dosed one drop daily and was approved with efficacy data at 24 hours post-dose.

Up to 30% of the U.S. population is affected by seasonal allergy symptoms, and up to 70% to 80% of these individuals experience ocular symptoms, such as itchy eyes.

Results from two clinical studies showed that olopatadine hydrochloride ophthalmic solution 0.7%, provided significantly improved relief of ocular itching associated with allergic conjunctivitis at 24 hours post-treatment compared with olopatadine 0.2% (Pataday solution, Alcon). The safety profile of the olopatadine 0.7% solution was comparable with that of olopatadine 0.2%. In the two studies, the most common adverse events included blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensations in the eye.

Pazeo solution 0.7% is expected to be available by prescription in the U.S. in March 2015.

Allergic conjunctivitis is not typically harmful to a person’s eyes or vision; however, it can cause discomfort. The most common subtypes of allergic conjunctivitis are seasonal allergic conjunctivitis, which lasts for a short period, and perennial allergic conjunctivitis, a chronic, year-round condition.

Source: Alcon; February 2, 2015.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential